According to the 2024 national medical insurance catalog released today, the "Breast Cancer Miracle Drug" DS8201, which Astrazeneca is responsible for negotiating, the injection of trastuzumab deruxtecan appeared in the list. Previously, the drug was listed for formal review in 2023, but did not make it into the 2023 medical insurance catalog. (Financial Network reporter Lu Afeng He Fan)
阿斯利康“乳腺癌ADC神药”DS-8201进入新版医保目录
Astrazeneca's "Breast Cancer ADC Miracle Drug" DS-8201 has entered the new version of the medical insurance catalog.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated